Please login to the form below

Not currently logged in
Email:
Password:

gabapentin enacarbil

This page shows the latest gabapentin enacarbil news and features for those working in and with pharma, biotech and healthcare.

US shortage of GSK’s restless legs syndrome treatment Horizant

US shortage of GSK’s restless legs syndrome treatment Horizant

In its notice, the US regulator said GSK is “ experiencing a backorder situation”, leaving an expected shortage of Horizant (gabapentin enacarbil) until June 2013 – one month after XenoPort assumes responsibility for

Latest news

  • GSK and XenoPort end restless legs syndrome collaboration GSK and XenoPort end restless legs syndrome collaboration

    The two companies reached an agreement that will see GSK return US rights to Horizant (gabapentin enacarbil) back to its developer XenoPort five years after the two companies signed a $640m

  • Horizant gets post-shingles pain indication in US

    The US FDA approved Horizant (extended-release gabapentin enacarbil) for the management of post-herpetic neuralgia (PHN) in adult patients on the strength of data from three clinical trials that showed

  • GSK sales fall for first quarter of 2011

    Recent approvals for GSK include lupus drug Benlysta (belimumab), Horizant (gabapentin enacarbil) for Restless Legs Syndrome and epilepsy treatment Trobalt (retigabine).

  • GSK Restless Legs Syndrome drug approved

    Syndrome. GlaxoSmithKline (GSK) and XenoPort have won marketing approval from the US Food and Drug Administration (FDA) for Horizant (gabapentin enacarbil), a non-dopaminergic treatment for moderate-to-severe primary Restless ... The drug, which was

  • GSK migraine study fails

    The drug, gabapentin enacarbil (GSK1838262/XP13512), is a new chemical entity that provides dose-proportional, sustained exposure of gabapentin using high-capacity transport mechanisms in the gastrointestinal tract.

More from news
Approximately 2 fully matching, plus 6 partially matching documents found.

Latest appointments

  • XenoPort appoints chief medical officer XenoPort appoints chief medical officer

    Dr Kim has been with the US biopharma company since July 2013, when he joined as VP of medical affair, supporting the marketing of Horizant (gabapentin enacarbil) in restless legs syndrome

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics